CI Cigna (CI) Insider Trading, Ownership & Congress Trades
Insurance · Hospital & medical service plans · CIK 0001739940
Congress · 1Form 144 · 3
Insider buyers, 180 days
0
Funds added, last quarter
849
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $39.3M priced
What the filings say about CI
Insiders, 180 days
-$65.7M net sold
4 sellers · 12% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 3 sold
Latest: sale, 2026-03-23
Planned sales (Form 144), 90 days
$6.3M
3 notices
Cigna insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cigna Group insiders sold a net $65.7M of stock across 121 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Mar 2, 2026.
- The trade is 12.2% of the 5,053 shares held after it.
- 1 other insider sold within 30 days.
- 849 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Neville Everett sold about $175.3K of CI under a 10b5-1 plan on Sep 3, 2026; 1 other insider sold within 30 days and 849 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Aug 4, 2026.
- The trade is 10.3% of the 25,880 shares held after it.
- 1 other insider sold within 30 days.
- 849 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Jones Nicole S sold about $748.5K of CI under a 10b5-1 plan on Aug 18, 2026; 1 other insider sold within 30 days and 849 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Mar 2, 2026.
- The trade is 71.3% of the 27,256 shares held after it.
- 1 other insider sold within 30 days.
- 849 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Jones Nicole S sold about $5.4M of CI on Aug 4, 2026; 1 other insider sold within 30 days and 849 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 38.0% of the 2,368 shares held after it.
- No other insider sold within 30 days.
- 849 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Kates Jamie G sold about $268.5K of CI on Jun 12, 2026; 849 funds added in the latest 13F quarter.Context
- 37 earlier Form 4 trades (code P or S) here by this insider (1 buy, 36 sales), the last on Nov 3, 2025.
- The trade is 1.7% of the 232,312 shares held after it.
- No other insider sold within 30 days.
- 849 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO Cordani David sold about $1.1M of CI on May 12, 2026; 849 funds added in the latest 13F quarter.121 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$65.7M over 180 days
-$6.3M over 90 days
below 92% of Insurance
Congress
1 member bought in the last year
the lowest in Insurance
Funds
849 funds bought in last quarter
more than 93% of Insurance
Revenue
+11.2% year over year
more than 56% of Insurance
Margin
2.2% net margin
below 77% of Insurance
Buybacks
$280.0M repurchased, FY to 2026-06-30
more than 63% of Insurance
Short interest
2.6% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
below 55% of Insurance
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.4%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CI: institutional holders (13F)
13F holdings, latest reported quarter
23,438,250 sh
$6.5B
17,276,296 sh
$4.8B
12,682,259 sh
$3.5B
12,173,875 sh
$3.4B
10,443,691 sh
$2.9B
Congress trades in CI
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-03-23 · disclosed 38 days later
$1,001 - $15,000
Sold 2026-03-13 · disclosed 25 days later
$1,001 - $15,000
Bought 2025-12-19 · disclosed 24 days later
$1,001 - $15,000
Sold 2025-12-18 · disclosed 28 days later
$1,001 - $15,000
Sold 2025-11-13 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Neville Everett
Filed 2026-09-03
$175.3K
Jones Nicole S
Filed 2026-08-18
$748.4K
Jones Nicole S
Filed 2026-08-04
$5.4M
CI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
GQG PARTNERS US SELECT QUALITY EQUITY FUND
$112.8M position · as of 2026-06-30
4.4%
NVIT GQG US Quality Equity Fund
$3.7M position · as of 2026-06-30
4.3%
GQG US Equity ETF
$24.3M position · as of 2026-06-30
4.3%
iShares U.S. Healthcare Providers ETF
$47.2M position · as of 2026-06-30
4.0%
Victory RS Investors Fund
$2.8M position · as of 2026-06-30
3.9%
Saratoga Health & Biotechnology Fund
$380.3K position · as of 2026-05-31
3.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
The Cigna Group Employee Political Action Committee
Cycle 2026 · $1,961K spent
$1.9M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · David M. Cordani
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$22.9M
$14.6M
$6.9M
+45%
+48%
2024
$23.3M
$18.9M
$8.1M
+42%
+29%
2023
$21.0M
$8.1M
$6.8M
+52%
+26%
2022
$21.0M
$57.4M
$6.3M
+65%
+24%
2021
$19.9M
$15.4M
$7.2M
+12%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $65.7M sold by insiders over 180 days, 849 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $6.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CI financials
Revenue growth
+11.2%
XBRL, annual
Net margin
2.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$282.4B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CI
| FY Dec 2025 | $274.9B |
| FY Dec 2024 | $247.1B |
| FY Dec 2023 | $195.3B |
| FY Dec 2022 | $180.5B |
| FY Dec 2021 | $174.1B |
| Jun 2026 | $71.7B |
| Mar 2026 | $68.5B |
| Dec 2025 | $72.5B |
| Sep 2025 | $69.7B |
| Jun 2025 | $67.2B |
| Mar 2025 | $65.5B |
| Dec 2024 | $65.6B |
| Sep 2024 | $63.7B |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM CI
| FY Dec 2025 | n/a |
| FY Dec 2024 | +1.4% |
| FY Dec 2023 | +2.6% |
| FY Dec 2022 | +3.8% |
| FY Dec 2021 | +3.1% |
| Jun 2026 | +2.3% |
| Mar 2026 | +2.4% |
| Dec 2025 | +1.3% |
| Sep 2025 | +2.8% |
| Jun 2025 | +2.3% |
| Mar 2025 | +2.0% |
| Dec 2024 | +1.8% |
| Sep 2024 | +1.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$9.2B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CI
| FY Dec 2025 | $8.6B |
| FY Dec 2024 | $9.3B |
| FY Dec 2023 | $10.8B |
| FY Dec 2022 | $7.6B |
| FY Dec 2021 | $6.1B |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.75x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity CI
| FY Dec 2025 | 0.75x |
| FY Dec 2024 | 0.78x |
| FY Dec 2023 | 0.67x |
| FY Dec 2022 | 0.70x |
| FY Dec 2021 | 0.71x |
| Jun 2026 | 0.75x |
| Mar 2026 | 0.73x |
| Dec 2025 | 0.75x |
| Sep 2025 | 0.81x |
| Jun 2025 | 0.77x |
| Mar 2025 | 0.76x |
| Dec 2024 | 0.78x |
| Sep 2024 | 0.78x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.32x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CI
| FY Dec 2025 | 0.31x |
| FY Dec 2024 | 0.32x |
| FY Dec 2023 | 0.38x |
| FY Dec 2022 | 0.28x |
| FY Dec 2021 | 0.21x |
| Jun 2026 | 0.32x |
| Mar 2026 | 0.29x |
| Dec 2025 | 0.31x |
| Sep 2025 | 0.25x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.24x |
| Dec 2024 | 0.32x |
| Sep 2024 | 0.20x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on equity CI
| FY Dec 2025 | n/a |
| FY Dec 2024 | +7.9% |
| FY Dec 2023 | +11.4% |
| FY Dec 2022 | +14.8% |
| FY Dec 2021 | +11.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +14.4% |
| Jun 2025 | +11.9% |
| Mar 2025 | +12.2% |
| Dec 2024 | +7.9% |
| Sep 2024 | +7.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets CI
| FY Dec 2025 | n/a |
| FY Dec 2024 | +2.2% |
| FY Dec 2023 | +3.5% |
| FY Dec 2022 | +4.5% |
| FY Dec 2021 | +3.5% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +3.8% |
| Jun 2025 | +3.2% |
| Mar 2025 | +3.3% |
| Dec 2024 | +2.2% |
| Sep 2024 | +2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.8%
operating income after a 19.2% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CI
| FY Dec 2025 | +11.4% |
| FY Dec 2024 | +9.9% |
| FY Dec 2023 | +12.0% |
| FY Dec 2022 | +9.5% |
| FY Dec 2021 | +8.5% |
| Jun 2026 | +11.8% |
| Mar 2026 | +11.9% |
| Dec 2025 | +11.4% |
| Sep 2025 | +10.6% |
| Jun 2025 | +10.8% |
| Mar 2025 | +11.5% |
| Dec 2024 | +9.9% |
| Sep 2024 | +13.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CI
| FY Dec 2025 | +9.2% |
| FY Dec 2024 | +9.3% |
| FY Dec 2023 | +8.3% |
| FY Dec 2022 | +7.9% |
| FY Dec 2021 | +6.9% |
| Jun 2026 | +10.1% |
| Mar 2026 | +9.8% |
| Dec 2025 | +9.2% |
| Sep 2025 | +8.9% |
| Jun 2025 | +9.3% |
| Mar 2025 | +9.3% |
| Dec 2024 | +9.3% |
| Sep 2024 | +9.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
12.69x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CI
| FY Dec 2025 | 12.40x |
| FY Dec 2024 | 22.67x |
| FY Dec 2023 | 17.21x |
| FY Dec 2022 | 15.38x |
| FY Dec 2021 | 14.55x |
| Jun 2026 | 11.40x |
| Mar 2026 | 11.30x |
| Dec 2025 | 12.40x |
| Sep 2025 | 12.75x |
| Jun 2025 | 18.10x |
| Mar 2025 | 18.28x |
| Dec 2024 | 22.67x |
| Sep 2024 | 32.65x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$106.7B
market value at close 2026-10-23 on 2026-07-24 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value CI
| FY Dec 2025 | $97.3B |
| FY Dec 2024 | $101.2B |
| FY Dec 2023 | $110.7B |
| FY Dec 2022 | $126.5B |
| FY Dec 2021 | $104.7B |
| Jun 2026 | $98.5B |
| Mar 2026 | $94.2B |
| Dec 2025 | $97.3B |
| Sep 2025 | $105.0B |
| Jun 2025 | $114.8B |
| Mar 2025 | $112.2B |
| Dec 2024 | $101.2B |
| Sep 2024 | $123.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+11.4%
TTM free cash flow over market value at close 2026-10-23
FCF yield CI
| FY Dec 2025 | +11.6% |
| FY Dec 2024 | +12.1% |
| FY Dec 2023 | +12.3% |
| FY Dec 2022 | +7.5% |
| FY Dec 2021 | +8.1% |
| Jun 2026 | +12.7% |
| Mar 2026 | +11.0% |
| Dec 2025 | +11.6% |
| Sep 2025 | +9.9% |
| Jun 2025 | +4.8% |
| Mar 2025 | +7.1% |
| Dec 2024 | +12.1% |
| Sep 2024 | +5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.39x
P/E over trailing EPS growth of 32%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing CI
| FY Dec 2025 | 0.15x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.42x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.35x |
| Mar 2026 | 0.36x |
| Dec 2025 | 0.15x |
| Sep 2025 | 0.11x |
| Jun 2025 | 0.42x |
| Mar 2025 | 0.38x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2025-12 | 2025-09 | 2025-06 | |
|---|---|---|---|---|
| Revenue | $274.9B | n/a | n/a | n/a |
| Operating income | $9.2B | n/a | n/a | n/a |
| Net income | $6.0B | n/a | n/a | n/a |
| EPS (diluted) | 22.18 | n/a | n/a | n/a |
| Operating cash flow | $9.6B | n/a | n/a | n/a |
| Cash | $7.7B | n/a | n/a | n/a |
| Long-term debt | $30.9B | n/a | n/a | n/a |
| Buybacks | $3.6B | n/a | n/a | n/a |
| Dividends paid | $1.6B | $396.0M | $402.0M | $401.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
CI Stock Sonar score 6/7 axes
Find similar shapesCompareCI ranks highest on profitability (62nd percentile) and growth (56th), and lowest on insider conviction (4th), among Insurance peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CI filings, in plain words
Are Cigna insiders buying or selling CI?
In the 180 days to 2026-10-27, Cigna insiders were net sellers, a net $65.7M across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded CI?
Yes. In the year to 2026-10-27, 1 House member disclosed buying CI and 3 House members disclosed selling it; the latest on record is a sale by Jared Moskowitz dated 2026-03-23.
Are there planned insider sales of CI?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $6.3M of stock; the latest, by Neville Everett, was filed 2026-09-03.
Read the full summary
In the 180 days to 2026-10-27, Cigna insiders were net sellers of CI, a net $65.7M across purchases and sales reported on Form 4 by 4 sellers. 12% of the 17 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying CI and 3 members disclosed selling it; the latest on record is a sale by Jared Moskowitz dated 2026-03-23. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $6.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
